Physician profile
Hyo-Joon Cha
NPI 1770060394
$1,292.25
in general payments reported to CMS, 2019-2025
15 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $40.54 · 2023: $194 · 2024: $468 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $360.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $302.26 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $122.41 | 2022-2025 | |
| Exact Sciences Corporation | $89.89 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $83.30 | 2024-2025 | Farxiga, Airsupra |
| Abbvie INC. | $67.50 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $61.71 | 2025 | Austedo Xr, Ajovy |
| Merck Sharp & Dohme LLC | $38.65 | 2023 | Belsomra |
| Xeris Pharmaceuticals, INC. | $29.08 | 2024-2025 | Gvoke Hypopen |
| Mauna Kea Technologies, INC. | $25.67 | 2021 | |
| Neurocrine Biosciences, INC. | $25.54 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.92 | 2024 | Jardiance |
| Sk Life Science, INC. | $22.37 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.20 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyo-Joon Cha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.